Metabolites (Dec 2018)

Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts

  • Paul L. Wood,
  • Michelle M. Donohue,
  • John E. Cebak,
  • Taylor G. Beckmann,
  • Márcia Cristina Fernandes Messias,
  • Laura Credidio,
  • Cláudio Saddy Rodrigues Coy,
  • Patrícia de Oliveira Carvalho,
  • Sara Crotti,
  • Sara D’Aronco,
  • Emanuele D.L. Urso,
  • Marco Agostini

DOI
https://doi.org/10.3390/metabo8040091
Journal volume & issue
Vol. 8, no. 4
p. 91

Abstract

Read online

Background: There are currently no blood-based biomarkers for early diagnosis of colorectal cancer. Previous research has suggested that very-long-chain dicarboxylic acid (VLCDCA) 28:4 might be such a biomarker. Methods: Using high-resolution mass spectrometry, we analyzed VLCDCA 28:4 in the plasma of colorectal cancer patients in Italian [n = 62] and Brazilian [n = 52] cohorts. Additionally, we investigated individuals diagnosed with familial adenomatous polyposis (FAP; n = 27), one of the most important clinical forms of inherited susceptibility to colorectal cancer. Results: Decrements in plasma levels of VLCDCA 28:4 were monitored in colorectal cancer patients. These decreases were independent of the stage of tumor development and the individual’s age. However, no decrements in VLCDCA 28:4 were monitored in FAP patients. Conclusions: The plasma levels of VLCDCA 28:4 represent a potential biomarker of sporadic colorectal cancer. In addition, it is possible that resupply of this anti-inflammatory lipid may represent a new therapeutic strategy for CRC and inflammatory disorders.

Keywords